CYP26C1 is not expressed in in colorectal cancer but detected in the liver.
| Inventor | Institute |
|---|---|
| Ayham Alnabulsi | Vertebrate Antibodies Limited |
| Cat. #: | 152157 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Digestive / Gastrointestinal cancer |
| Research Fields: | Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology |
| Application: | IHC ; WB |
| Target: | Cytochrome P450, family 26, subfamily C, polypeptide 1 (CYP26C1) |
| Reactivity: | Human ; Mouse ; Rat |
| Clone: | T6P1C7*E7 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | CYP26C1 is not expressed in in colorectal cancer but detected in the liver. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | Ovalbumin-conjugated synthetic peptide RWELATPAFP (C-terminal sequence) |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | CYP26C1 is not expressed in in colorectal cancer but detected in the liver. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339. The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.